Andrew J. Armstrong, MD, MSc, is a genitourinary oncologist at Duke Health in Durham, N
AI-Derived Biomarker Predicts Benefit of Long-Term ADT in Prostate Cancer
Andrew J. Armstrong, MD, ScM, discusses the methods behind a study that established a digital pathology biomarker for the benefit of androgen deprivation therapy in localized high-risk prostate cancer.
Safety Profile of LuPSMA Therapy in mCRPC
Dr Andrew J. Armstrong reviews the safety of LuPSMA therapy as compared to cabazitaxel as seen in the phase 2 TheraP trial and comments on sequencing strategies for patients with metastatic castration-resistant prostate cancer.
Patient Selection of LuPSMA Therapy in mCRPC
An expert in prostate cancer comments on the appropriate patient population for Lutetium-177 PSMA-617 therapy for the management of metastatic castration-resistant prostate cancer.
Phase 3 VISION Trial in PSMA-Positive mCRPC
Dr Andrew J. Armstrong reviews the phase 3 VISION trial evaluating the use of LuPSMA therapy in patients with progressive PSMA-positive metastatic castrate-resistant prostate cancer.
Response to LuPSMA Therapy in mCRPC
Andrew J. Armstrong, MD, MSc, discusses the survival benefit of LuPSMA therapy in patients with metastatic castration-resistant prostate cancer and evaluates the response to therapy compared with other agents.
Standard of Care for PSMA-Positive mCRPC
Andrew J. Armstrong, MD, MSc, provides insight on unmet needs and the use of androgen receptor inhibitors for patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.